Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$41.64 USD
+0.49 (1.19%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $42.44 +0.80 (1.92%) 7:58 PM ET
4-Sell of 5 4
D Value C Growth D Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Tarsus Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
TARS 41.64 +0.49(1.19%)
Will TARS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Will Declining Medical Customers Affect Cigna's Q1 Earnings?
Wall Street Analysts See a 31.89% Upside in Tarsus Pharmaceuticals (TARS): Can the Stock Really Move This High?
Other News for TARS
Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.48 misses by $0.10, revenue of $102.7M beats by $6.89M
Tarsus Pharmaceuticals reports Q2 EPS (48c), consensus (36c)
Tarsus Pharmaceuticals Q2 2025 Earnings: Revenue Surpasses Estimates at $102. ...
Earnings Scheduled For August 6, 2025
Earnings To Watch: Tarsus Pharmaceuticals Inc (TARS) Reports Q2 2025 Result